Table 2c.
Autologous Patient Outcomes
| Home HCT (N=17) | Matched Controls (N=34) | P-value1 | |
|---|---|---|---|
| Mean Number of Clinic Visits (IQR) | 5 (2–8) | 12.3 (11–16) | <0.001 |
| Mean Days Hospitalized (IQR) | 4.6 (0–8) | 3.7 (0–8.8) | 0.92 |
| Mean Percent Time Hospitalized (IQR) | 21% (0%–33%) | 27% (0%–41 %) | 0.10 |
| Median Days to Engraftment (IQR) | 12 (12–13) | 11 (11–12) | 0.07 |
| Median Days to Discharge (IQR) | 19 (16–23, | 16.5 (14–18) | 0.004 |
| Incidence of Febrile Neutropenia | 11 (64.7%) | 27 (79.4%) | 0.31 |
| Median Days of Febrile Neutropenia (IQR) | 5 (4–7) | 4 (3–5) | 0.22 |
| Clinically-Significant BSI2 Peri-Transplant | 5 (29.4%) | 4 (11.8%) | 0.14 |
| LCBI3 Peri-Transplant | 4 (23.5%) | 2 (5.9%) | 0.09 |
| MBI-LCBI4 Peri-Transplant | 1 (5.9%) | 2 (5.9%) | 0.99 |
| Respiratory Infection Peri-Transplant | 0 (0%) | 2 (5.9%) | 0.55 |
| C. difficile Infection, Peri-Transplant | 0 (0%) | 2 (5.9%) | 0.55 |
| Clinically-Significant BSI2 1 Year Post-Transplant | 5 (29.4%) | 4 (11.8%) | 0.14 |
| LCBI3 1 Year Post-Transplant | 4 (23.5%) | 2 (5.9%) | 0.09 |
| MBI-LCBI4 1 Year Post-Transplant | 1 (5.9%) | 2 (5.9%) | 0.99 |
| Respiratory Infection 1 Year Post-Transplant | 1 (5.9%) | 2 (5.9%) | 0.99 |
| C. difficile Infection 1 Year Post-Transplant | 0 (0%) | 2 (5.9%) | 0.55 |
| Relapse 1 Year Post-Transplant | 0 (0%) | 7 (20.6%) | 0.08 |
| Mortality 1 Year Post-Transplant | 0 (0%) | 2 (5.9%) | 0.55 |
1
P-values obtained via t-test or Chi-square test.
2
BSI: Bloodstream Infection.
3
LCBI: Laboratory-Confirmed Bloodstream Infection.
4
MBI-LCBI: Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infection.